Ftse Mib
34.834,30
0,95%
DAX
18.652,67
0,44%
S&P 500
5.352,96
-0,02%
NASDAQ
17.173,12
-0,09%
Bitcoin
70.825,17
0,09%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Quince Therapeutics Inc (QNCX) Quince Therapeutics Inc (QNCX) Notizie

QNCX

Quince Therapeutics (QNCX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:QNCX
DataOraFonteTitoloSimboloCompagnia
06/06/202423:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QNCXQuince Therapeutics Inc
05/06/202420:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
03/06/202413:00Business WireQuince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex SystemNASDAQ:QNCXQuince Therapeutics Inc
13/05/202413:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QNCXQuince Therapeutics Inc
13/05/202413:00Business WireQuince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsNASDAQ:QNCXQuince Therapeutics Inc
06/05/202422:05Business WireQuince Therapeutics to Present at The Citizens JMP Life Sciences ConferenceNASDAQ:QNCXQuince Therapeutics Inc
01/04/202413:00Business WireQuince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial ResultsNASDAQ:QNCXQuince Therapeutics Inc
22/02/202413:00Business WireQuince Therapeutics Launches Scientific Advisory BoardNASDAQ:QNCXQuince Therapeutics Inc
15/02/202413:00Business WireQuince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of DirectorsNASDAQ:QNCXQuince Therapeutics Inc
07/02/202422:05Business WireQuince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:QNCXQuince Therapeutics Inc
05/01/202422:01Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:QNCXQuince Therapeutics Inc
04/01/202422:05Business WireQuince Therapeutics to Participate at Investor Events in January 2024NASDAQ:QNCXQuince Therapeutics Inc
25/10/202301:34Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:QNCXQuince Therapeutics Inc
23/10/202313:00Business WireQuince Therapeutics Completes Acquisition of EryDel S.p.A.NASDAQ:QNCXQuince Therapeutics Inc
28/09/202322:53Dow Jones NewsQuince Therapeutics to Advance Study of EryDex as FDA Lifts Application HoldNASDAQ:QNCXQuince Therapeutics Inc
28/09/202322:05Business WireU.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-TelangiectasiaNASDAQ:QNCXQuince Therapeutics Inc
06/09/202313:00Business WireQuince Therapeutics Appoints Dr. Charles S. Ryan as PresidentNASDAQ:QNCXQuince Therapeutics Inc
10/08/202322:05Business WireQuince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023NASDAQ:QNCXQuince Therapeutics Inc
24/07/202323:56Business WireQuince Therapeutics rileva EryDel SpA e il suo asset di fase 3 mirato all'atassia-telangectasia, per cui attualmente non esistono trattamenti approvati, con opportunità stimate per un picco di vendite di oltre 1 miliardo di dollari USANASDAQ:QNCXQuince Therapeutics Inc
24/07/202313:00Business WireQuince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales OpportunityNASDAQ:QNCXQuince Therapeutics Inc
26/05/202323:51Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:QNCXQuince Therapeutics Inc
25/05/202322:26Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:QNCXQuince Therapeutics Inc
14/04/202322:13Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:QNCXQuince Therapeutics Inc
14/04/202322:07Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:QNCXQuince Therapeutics Inc
11/04/202313:00Business WireQuince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake CapitalNASDAQ:QNCXQuince Therapeutics Inc
06/04/202322:05Business WireQuince Therapeutics Engages MTS Health Partners as Independent Financial AdvisorNASDAQ:QNCXQuince Therapeutics Inc
05/04/202323:16Edgar (US Regulatory)Securities Registration (section 12(b)) (8-a12b)NASDAQ:QNCXQuince Therapeutics Inc
05/04/202322:05Business WireQuince Therapeutics Adopts Limited Duration Stockholders Rights PlanNASDAQ:QNCXQuince Therapeutics Inc
31/03/202322:01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:QNCXQuince Therapeutics Inc
22/03/202310:00Business WireQuince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake CapitalNASDAQ:QNCXQuince Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:QNCX

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STMMI
ST Microelectronics
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
IVG
Iveco Group NV
BIT
BPE
Bper Banca
BIT
SPM
Saipem
BIT
RACE
Ferrari NV
BIT
PST
Poste Italiane S.p.a
BIT
TIT
Telecom Italia
BIT
LDO
Leonardo
BIT
FBK
Finecobank
BIT
CPR
Davide Campari
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network